US equities |
MU $1,079.04 ▲+1.31% NVDA $231.32 ▲+1.29% SNDK $1,776.90 ▲+2.13% INTC $121.21 ▲+0.82% TSLA $357.45 ▲+0.74% GOOGL $338.88 ▼-1.51% SPCX $150.03 ▼-0.55% AMD $616.33 ▲+0.75%
FinancialContent Watchlist

Articles published by Vera Therapeutics

< Previous 1 2 3 4 Next >
News headline image
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Appoints Christopher Hite to Board of Directors
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
News headline image
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
< Previous 1 2 3 4 Next >